Scotland · NHS Scotland MSAN
Oxybutynin (Kentera®) 3.9mg/24hours transdermal patches
MSAN(2026)5 · Level 2 · issued 30 Jan 2026
What the notice states
The supply position for each affected product, as recorded in the notice — read the full signed PDF above for the clinical advice and actions.
| Product | Position | Resupply |
|---|---|---|
| 1. Oxybutynin (Kentera®) 3.9mg/24hours transdermal patches are out of stock until late-February | Out of stock | late-February |
| 2. Oxybutynin 5mg and 10mg modified-release tablets remain available and can support | Available | — |
| 3. Oxybutynin 2.5mg/5ml and 5mg/5ml oral solutions sugar free remain available and can support | Available | — |
| 4. Oxybutynin 2.5mg and 5mg tablets remain available but cannot support increased demand. | Available — cannot support uplift | — |
| 5. Alternative anticholinergic/non-anticholinergic agents for urinary incontinence remain available | Available | — |
| is the main reason for discontinuing oxybutynin. As many of the adverse effects of | Discontinued | — |
| Note: Tolterodine presentations cannot support increased demand. | Available — cannot support uplift | — |
| you need to register with the SPS website. Registration for access to the website is available to | Available | — |
From the NHS Scotland notice PDF (linked above); dates and “valid until” text are as stated, fuzzy wording kept as written. Scotland is covered separately from England — see methodology. Not an official NHS service, and not clinical advice — follow the guidance issued to your pharmacy.